CymaBay Announces FDA Acceptance Of NDA, Priority Review For Seladelpar; Stock Up 24%

CymaBay Therapeutics, Inc. (CBAY) announced on Monday that the U.S. Food and Drug Administration has accepted its New Drug Application or NDA, and granted a priority review for Seladelpar for the treatment of primary biliary cholangitis or PBC.

PBC is a rare, chronic liver inflammatory disease which eventually leads to liver cirrhosis.

The company said that the FDA has set a Prescription Drug User Fee Act or PDUFA target action date of August 14.

Currently, CymaBay's stock is surging 24.52 percent, to $31.99 over the previous close of $25.69 on a volume of 21,183,216 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Next Story
Editors Pick
Court Orders Elon Musk To Testify In SEC's Twitter Probe
A U.S. Federal judge ordered Tesla Inc. and SpaceX CEO Elon Musk to testify in an investigation by the U.S. Securities and Exchange Commission regarding his 2022 acquisition of social media platform Twitter, now re-branded as X. The federal regulator is probing whether Musk or anyone else, committed securities fraud in 2022 as he purchased Twitter stock ahead of his buyout of the firm.
Uber Eats Edits Super Bowl Ad After Backlash
Uber Eats has edited its Super Bowl advertisement, removing a portion that joked about dangerous peanut allergies. The food delivery firm had faced severe backlash for making fun of food allergies, which could cause millions of people to struggle for their lives. Super Bowl commercials are featured in the U.S. television broadcast of the Super Bowl...
PepsiCo Q4 Adj. EPS Tops Estimates, But Revenues Miss
Snack and beverage giant PepsiCo Inc. (PEP) on Friday reported that net income for the fourth quarter soared from last year, reflecting lower impairment of intangible assets this year and 18 percent revenue growth in Latin America. Core earnings per share topped analysts' estimates, while annual revenues miss it.